Evidence map›Paper›PMID 42375519›Full record

ArticleiScience2026

CDC20 promotes prostate cancer progression via modulating c-MYC and PI3K-AKT signaling.

Jixiang Ding, Xinyu Xu, Ningning Zhang, Jiaojiao Chen, Wenhui Zhu, Ke Lu, Chaozhong Wang, Zhenyu Fu, Jing Zhai, Yizhou Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jixiang DingDepartment of Urology, Affiliated Hospital of Nantong University, Nantong City, Jiangsu Province, China.
Xinyu XuDepartment of Urology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ningning ZhangDepartment of Anesthesiology, Huashan Hospital, Fudan University, Shanghai, China.
Jiaojiao ChenNursing Department, Huashan Hospital, Fudan University, Shanghai, China.
Wenhui ZhuDepartment of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Ke LuDepartment of Urology, Affiliated Changshu Hospital of Nantong University, Changshu, China.
Chaozhong WangDepartment of Urology, Affiliated Changshu Hospital of Nantong University, Changshu, China.
Zhenyu FuDepartment of Urology, Affiliated Changshu Hospital of Nantong University, Changshu, China.
Jing ZhaiDepartment of Urology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yizhou WangDepartment of Urology, Affiliated Changshu Hospital of Nantong University, Changshu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer shows substantial variability in clinical outcomes, underscoring the need for reliable biomarkers and mechanistic insights. Analysis of The Cancer Genome Atlas data identified CDC20 as an independent prognostic factor with elevated expression in prostate cancer. Functional studies in DU145 and PC-3 cells demonstrated that CDC20 promotes cell proliferation, migration, invasion, and cell cycle progression. Co-immunoprecipitation and loss-of-function analyses indicated that CDC20 interacts with c-MYC and influences PI3K-AKT signaling. In a xenograft model, CDC20 knockdown reduced tumor growth, whereas its overexpression enhanced tumor progression. These findings suggest that CDC20 contributes to prostate cancer progression, at least in part, through a c-MYC-associated PI3K-AKT signaling axis, and support its potential relevance for prognostic assessment and therapeutic targeting.

Indexed as

Health sciencesInternal medicineMedical specialtyMedicineOncology

Identifiers

PMID42375519
PMCPMC13311138

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.